Plasma MicroRNA for Prediction of Hepatocellular Carcinoma

Benha University100 enrolled

Overview

100 patients with diagnosed HCV were evaluated by clinical and ultrasound examination and were categorized as uncomplicated HCV (n=22) and complicated HCV (n=78). All patients were evaluated for hepatosteatosis and liver fibrosis using the computerized hepatorenal index, the hepatic steatosis index, aspartate aminotransferase (AST)/platelet count index (APRI) and the Fibrosis-4 (FIB-4) scores. Blood samples were obtained for estimation of serum levels of liver function tests and plasma levels of microRNA 21 and 126.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Hepatitis C

Interventions

Blood SamplingBIOLOGICAL

Blood sampling under a complete aseptic conditions

Eligibility

Sex: ALLMin age: 31 YearsMax age: 67 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Complicated hepatitis C by HCC * Complicated hepatitis C by liver cirrhosis * Complicated hepatitis C by steatohepatitis * uncomplicated hepatitis C Exclusion Criteria: * pre-portal fibrosis secondary to previous bilharzial disease * pre-portal fibrosis secondary to alcoholic fatty liver * The presence of hepatic malignancy other than HCC * decompensated cirrhosis * hepatorenal failure * hepatic manifestations of congestive heart failure.

Locations (1)

Benha university

Banhā, El- Qalyobia, Egypt

Outcomes

Primary Outcomes

Relation between MicroRNA and HCV

The ability of estimation of plasma microRNA 21 and 126 to differentiate between uncomplicated and complicated HCV patients

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.